Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03532295 · ClinicalTrials.gov registry record · Phase 2
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT03532295 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 51 participants.
The verdict
NCT03532295, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
In this study, the investigators propose to combine retifanlimab with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The investigators hypothesize that this combination provides a powerful synergy between RT and immune modulators to produce more robust anti-tumor immune response, induce tumor regression and improve overall survival.
Interventions
- DRUG Bevacizumab
- DRUG Retifanlimab
- DRUG Epacadostat
- RADIATION Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2025-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03532295
The ClinicalTrials.gov registry entry for NCT03532295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT03532295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03532295 about?
NCT03532295 is a clinical study titled "Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas". In this study, the investigators propose to combine retifanlimab with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). The investigators hypothesize that this combination provides a powerful synergy between RT and immune modulators ...
What is the current status of trial NCT03532295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-04-20. Estimated completion is 2025-10-31.
What interventions are being tested in trial NCT03532295?
The interventions under investigation include: Bevacizumab (DRUG), Retifanlimab (DRUG), Epacadostat (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03532295?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.